Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Dong-A St Co. Ltd. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners, meaning each official is reviewing one case. The portfolio is spread across 2 distinct art units, indicating some technical variety within the biotechnology sector. This distribution of 3 pending actions across 3 distinct examiners requires the company to manage three separate examiner relationships simultaneously.
ONDACHI, PAULINE WANJIKU MUCH is the busiest examiner with 1 pending office action. With 3 pending actions and 2 art units, the company faces a relatively concentrated administrative environment despite the involvement of 3 distinct examiners. This structure allows for some comparison of examiner behavior within the same technical divisions, as the 2 distinct art units provide the primary procedural framework. Practitioners should focus on identifying the specific trends within the 2 distinct art units to better predict the behavior of the 3 distinct examiners. While each of the 3 pending office actions must be addressed individually, the departmental standards of the 2 art units will provide the necessary context for successful prosecution.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §102 only | 2 (50%) |
| §112 only | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ONDACHI, PAULINE WANJIKU MUCH | 1 | 100.0% | +0.0% |
| HELM, CARALYNNE E | 1 | 28.9% | +49.6% |
| BOWLES, DAVID PAUL | 1 | 72.7% | +22.4% |
| ADLAM, CHANTAL PETA-GAYE | 1 | 53.5% | +27.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18861369 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | ONDACHI, PAULINE WANJIKU MUCH | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688439 | PERCUTANEOUS ABSORPTION PREPARATION FOR TREATING DEMENTIA COMPRISING MEMANTINE ENANTHATE | HELM, CARALYNNE E | 23d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688439 | PERCUTANEOUS ABSORPTION PREPARATION FOR TREATING DEMENTIA COMPRISING MEMANTINE ENANTHATE | HELM, CARALYNNE E | 23d overdue |
| 17997252 | LONG-ACTING GLP-1 AND GLUCAGON RECEPTOR DUAL AGONIST | BOWLES, DAVID PAUL | 34d |
| 17906745 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | ADLAM, CHANTAL PETA-GAYE | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1654 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18861369 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | ONDACHI, PAULINE WANJIKU MUCH | — | §102 | Non-Final OA | — | Pending | Oct 29, 2024 |
| 18688439 | PERCUTANEOUS ABSORPTION PREPARATION FOR TREATING DEMENTIA COMPRISING MEMANTINE ENANTHATE | HELM, CARALYNNE E | 1615 | §103 | Final Rejection | 23d overdue | Pending | Mar 01, 2024 |
| 17997252 | LONG-ACTING GLP-1 AND GLUCAGON RECEPTOR DUAL AGONIST | BOWLES, DAVID PAUL | 1654 | §112 | Non-Final OA | 34d | Pending | Oct 27, 2022 |
| 17906745 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | ADLAM, CHANTAL PETA-GAYE | 1622 | §102 | Non-Final OA | — | Pending | Sep 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial